Literature DB >> 1304405

The clinical significance of measuring different anti-dsDNA antibodies by using the Farr assay, an enzyme immunoassay and a Crithidia luciliae immunofluorescence test.

E Werle1, M Blazek, W Fiehn.   

Abstract

Anti-double-stranded DNA (dsDNA) antibodies are highly specific for the diagnosis of systemic lupus erythematosus (SLE) but are heterogeneous in respect to, for example, avidity, class and cross-reactivity. Sera from 2061 patients were measured by three methods: an enzyme-linked immunosorbent assay (ELISA), an indirect immunofluorescence test with Crithidia luciliae as substrate (CLIF), and the Farr assay, a radioimmunological method based on the ammonium sulfate precipitation of immune complexes. The different anti-dsDNA antibody determinations were evaluated by analysis of patient records. The reason for a reactive Farr assay in 14 patients was predominantly the measurement of antibodies of the IgM class, which are not detected by the ELISA. The detection of additional antibodies to dsDNA of the IgA class, to single-stranded DNA or to histones plays a minor role. In comparison with the Farr assay, we found more positive results with the ELISA, which additionally detects anti-dsDNA antibodies of low avidity. The ELISA might also yield positive values in conditions such as chronic liver diseases, various infections and connective tissue diseases other than SLE. Avoiding the disadvantages of radioactivity, the ELISA is well suited as a screening test for dsDNA antibodies. However, positive results should be confirmed by the CLIF test or preferably by the Farr assay, thus combining sensitivity with specificity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1304405     DOI: 10.1177/096120339200100606

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  8 in total

Review 1.  The use of laboratory tests in the diagnosis of SLE.

Authors:  W Egner
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

2.  The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation.

Authors:  H Bootsma; P E Spronk; E J Ter Borg; E J Hummel; G de Boer; P C Limburg; C G Kallenberg
Journal:  Ann Rheum Dis       Date:  1997-11       Impact factor: 19.103

3.  Use of Rheumatology Laboratory Studies Among Primary Pediatricians.

Authors:  Colleen K Correll; Logan G Spector; Lei Zhang; Bryce A Binstadt; Richard K Vehe
Journal:  Clin Pediatr (Phila)       Date:  2016-07-19       Impact factor: 1.168

4.  Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4.

Authors:  Heikki Julkunen; Susanne Ekblom-Kullberg; Aaro Miettinen
Journal:  Rheumatol Int       Date:  2011-06-26       Impact factor: 2.631

5.  Anti-double stranded DNA antibodies: A rational diagnostic approach in limited-resource settings.

Authors:  Brahim Admou; Fatima-Ezzohra Eddehbi; Lahcen Elmoumou; Saad Elmojadili; Abdelmouïne Salami; Mohammed Oujidi; Imane Brahim; Raja Hazime
Journal:  Pract Lab Med       Date:  2022-06-03

6.  Anti-telomere antibodies in systemic lupus erythematosus (SLE): a comparison with five antinuclear antibody assays in 430 patients with SLE and other rheumatic diseases.

Authors:  E M Salonen; A Miettinen; T K Walle; S Koskenmies; J Kere; H Julkunen
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

7.  Clinical phenotype associations with various types of anti-dsDNA antibodies in patients with recent onset of rheumatic symptoms. Results from a multicentre observational study.

Authors:  Michele Compagno; Ole P Rekvig; Anders A Bengtsson; Gunnar Sturfelt; Niels H H Heegaard; Andreas Jönsen; Rasmus Sleimann Jacobsen; Gro Ø Eilertsen; Christopher G Fenton; Lennart Truedsson; Johannes C Nossent; Søren Jacobsen
Journal:  Lupus Sci Med       Date:  2014-04-01

8.  Detection in whole blood of autoantibodies for the diagnosis of connective tissue diseases in near patient testing condition.

Authors:  Makoto Miyara; Jean-Luc Charuel; Sasi Mudumba; Alice Wu; Pascale Ghillani-Dalbin; Zahir Amoura; Rufus W Burlingame; Lucile Musset
Journal:  PLoS One       Date:  2018-08-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.